More Generalized Anxiety Disorder Patients Switch from Branded Antidepressants to Atypical Antipsychotics than Between Ant

Decision Resources Unveils New Online Platform for Its Treatment Algorithms Service

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that among recently treated generalized anxiety disorder (GAD) patients, a higher percentage of switching occurred from branded antidepressants to atypical antipsychotics than between branded antidepressants. The findings, from the analysis of patient-level claims data from the fourth quarter of 2010, suggest that failure of a branded selective serotonin reuptake inhibitor (SSRI) or serotonin/norepinephrine reuptake inhibitor (SNRI) will result in a switch to an atypical antipsychotic rather than a switch within or between antidepressant drug classes.

The analysis is from Treatment Algorithms in Generalized Anxiety Disorder, which also finds that only 7.7 percent of recently treated GAD patients received atypical antipsychotics in the fourth quarter of 2010.

“Although the number of patients progressing to atypical antipsychotics is small, these agents captured a large percentage of new business during the last quarter of 2010 when compared with other drug classes, primarily from patients adding or switching to these agents when progressing to later lines of therapy,” said Decision Resources Analyst Jonathon Loring. “Treatment-resistant GAD patients present an opportunity for branded atypical antipsychotic agents such as AstraZeneca’s Seroquel and Bristol-Myers Squibb/Otsuka Pharmaceuticals’ Abilify as atypical antipsychotics have proven efficacious in treatment-resistant GAD patients, and these agents have a better side effect profile than other drugs in this class.”

Enhanced Service and Platform Now Available

The analysis is part of Decision Resources’ enhanced Treatment Algorithms series, which features a new online platform. Interactive, user-friendly and with more graphical data views, the new platform enables users to easily toggle between diseases and time cohorts, which ultimately allows for more in-depth analysis on each line of therapy. Treatment Algorithms analysis is now updated quarterly to provide ongoing trending of product utilization by line of therapy and new therapy initiations. Through examination of U.S. patient-level claims data, Decision Resources’ Treatment Algorithms series provides exceptional insight into physicians’ prescribing trends, from diagnosis through multiple courses of treatment, for a specific disease.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.



CONTACT:

Decision Resources
Lisa Osgood, 781-993-2606
[email protected]
or
Decision Resources, Inc.
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Monday, Bernstein analysts echoed what many were probably thinking about Novo Nordisk’s Rybselsus price: “Finally we can stop talking about it.”

Low interest rates and strong stock valuations are two top reasons why U.S. drugmakers are on the move for deals.

Despite a 45% premium offered to Allergan investors through the AbbVie buyout, one investor is suing to block the deal.